Baxter International, Inc. has been granted marketing authorization for Celvapan H1N1 pandemic vaccine from the European Commission. Celvapan H1N1 is the first cell culture-based and non-adjuvanted pandemic flu vaccine to receive marketing authorization in the EU. Baxter continues to deliver vaccine to national health authorities that have agreements with the company. Initial quantities of vaccine have already been received by a number of countries, including the UK and Ireland. Baxter is ...